3 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow marizomib: new trials by email Literature Review of marizomib trials Research Report on marizomib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Marizomib Central Nervous System (CNS) Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2024-03-01 | 2024-07-16 | |
| Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Marizomib - Anaplastic Ependymoma, Ependymoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2020-01-22 | 2022-07-27 |
| Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Phase 2 | Completed | Aadi Bioscience, Inc. | 62 | 2018-08-01 | 2023-11-07 |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab MRZ, BEV - Malignant Glioma, Glioblastoma | Phase 1 / Phase 2 | Completed | Celgene | 121 | 2015-04-15 | 2022-06-08 |
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma MRZ 0.5 mg/m^2 - Multiple Myeloma | Phase 2 | Completed | Celgene | 15 | 2007-03-01 | 2017-12-19 |
Multiple Myeloma (2) · Brain Neoplasms (1) · Disease Progression (1) · Ependymoma (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Recurrence (1)
Celgene (2) · Aadi Bioscience, Inc. (1) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1)
United States (5) · Canada (1)
Clifton Mo, MD (1) · Ileana Elias, MD (1) · Mark R Gilbert, M.D. (1) · Steven D Reich, MD (1)